Navigation Links
MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Date:11/26/2007

isease.

About MedImmune's Anti-GM-CSFR Antibody Development Program

In 2001, MedImmune's Cambridge facility (then known as Cambridge Antibody Technology) and AMRAD Operations Pty Ltd., now owned by CSL Limited, entered into a collaboration to jointly discover and develop human MAb therapeutics that neutralize the GM-CSF receptor, including CAM-3001. Under the terms of a subsequent licensing agreement entered into in August 2007, CSL will receive upfront and milestone payments, as well as royalties, on future sales of CAM- 3001. Additional terms of the agreement have not been disclosed.

About Rheumatoid Arthritis

Rheumatoid arthritis is a chronic systemic inflammatory disease that is associated with significant morbidity and mortality. The disease is characterized by inflammation of the synovial joints that can result in pain, swelling and joint damage with secondary deformity and progressive disability. Despite current treatment options, there is a significant mortality associated with RA, especially the more severe forms of the disease. There is need for additional treatments to control moderate to severely active disease. A new treatment is needed that may provide a significant clinical benefit for disease remission, as well as inhibiting progressive joint damage, and improving quality of life in patients with RA.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
3. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
4. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
5. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
6. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)... Findings Confirm Potency of Poly-ICR as...FirstCall/ -- Nventa Biopharmaceuticals,Corporatio...eclinical,studies using its proprietary Toll-like ...R), at the World Vaccine Congress 2008 in Lyon, Fr...potent vaccine adjuvant,targeting the Toll-like Re...
(Date:10/7/2008)... FLINT, Mich., Oct. 7 /- McLaren ...re gathering some of the world,s leading medical,m...globe on breast and,gastrointestinal cancer treatm...n and GLCI, was organized by McLaren,s Sukamal Sah...e work in sentinel node mapping for,colorectal can...
(Date:10/7/2008)... VANCOUVER, Oct. 7 / Bu...d today that its Puratein(R) and,Supertein(TM) can...d As,Safe) for their intended use in a variety of ...been self-affirmed GRAS through an,independent eva...lds of,food safety, toxicology, nutritional scienc...
(Date:10/7/2008)... FORT COLLINS, Colo., Oct. 7 /- A...examining embryonic stem cell self-renewal,report...lastim (recombinant,human serum albumin) was an ef...cell culture., The article entitled, "The ground ...sed that researchers used Cellastim as a recombina...
Breaking Medicine Technology:Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3Nobel Prize Awarded to Foundation for Biomedical Research Board Member 486 1Nobel Prize Awarded to Foundation for Biomedical Research Board Member 486 2Increase in ethanol production from corn could significantly impact 749 1Increase in ethanol production from corn could significantly impact 749 2Increase in ethanol production from corn could significantly impact 749 3EPI Says California Health Care Reform Bill is Misguided 3346 1DuPont Pledges 24250 000 to Nature Conservancy for Water Quality Initiative 3341 1DuPont Pledges 24250 000 to Nature Conservancy for Water Quality Initiative 3341 2DuPont Pledges 24250 000 to Nature Conservancy for Water Quality Initiative 3341 3DuPont Pledges 24250 000 to Nature Conservancy for Water Quality Initiative 3341 4
... from the ASSERT Trial Presented at EULAR, BARCELO... Data,presented today at the European League Again...Rheumatology showed that patients with,ankylosing ...mab),over two years experienced significant improv...eated patients showed sustained,reductions in spin...
...sults Published in Cancer Research, TARRYTOWN, N.Y...,Corporation today announced the results of scient...MPC-6827) is effective in treating,multiple types ...hanism by which MPC-6827 exerts its effects, and (...proteins known to be involved,in cancer drug resis...
Other Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
...ent of a transfusion-free surgical program for Jeh...tation also has helped// reduce the overall use of...oing the procedure, according to a study in the Se...one of the JAMA/Archives journals. "Orthotopic liv...
...luding registered nurses and doctors from Doctors ...d on the Contra Costa County Board of Supervisors/...ed a unanimous vote from the hospital’s board of d...ment to file for bankruptcy. Nurse Tami Roncskevit...
...e revealed that increased levels of lipoprotein(a)...r events// in healthy women according to Boston-ba...recommend generalized screening of lipoprotein(a) ...ly extremely high levels were associated with card...
...ent research, consumption of fatty fish like salmo...p in protection against kidney cancer//. A big, 1...sing on their consumption of fatty and lean fish a...concluded that those who ate great amounts of fatt...
Other Medicine News:Health News:Transfusion-Free Surgical Program Helpful for Liver Transplantation Patients 2Health News:Transfusion-Free Surgical Program Helpful for Liver Transplantation Patients 3Health News:Bankruptcy forces Hospital staff to Call For County Takeover 2Health News:Bankruptcy forces Hospital staff to Call For County Takeover 3Health News:High lipoprotein Levels in women Linked to Cardiovascular Risk 2Health News:Fatty Fish consumption may reduce Kidney Cancer risk 2Health News:Fatty Fish consumption may reduce Kidney Cancer risk 3
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: